What was the design of the ReNeu trial examining mirdametinib in NF1-PN?
The multicenter, single-arm ReNeu study enrolled patients at least 2 years of age with symptomatic, inoperable NF1-associated PN causing significant morbidity; of the 114…
Mirdametinib Shows Improved ORR Over Time in NF1-Associated Symptomatic Plexiform Neurofibroma
